Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Opemalirsen (AZD2373)

Phase 1Small molecule

1

Indications

1

Total Trials

0

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal ImpairmentCompleted

Renal ImpairmentPhase 1

Completed

Clinical

Trials by Indication[1]

Renal Impairment1 trial

A Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT07154901·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Opemalirsen (AZD2373). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Opemalirsen (AZD2373) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Opemalirsen (AZD2373). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

Related News